Plasma nuclear and mitochondrial DNA levels in acute myocardial infarction patients

Objective Plasma nuclear and mitochondrial DNA (mtDNA) levels are altered in many diseases. However, it is not known whether they are also altered in acute myocardial infarction (AMI). In the present study, we examined plasma nuclear and mtDNA levels in the patients with AMI before and after a percutaneous coronary intervention (PCI) to explore their potential as biomarkers. Methods and results Plasma nuclear and mtDNA levels were measured by quantitative PCR in 25 AMI patients, 25 non-myocardial infarction (MI) control participants (with MI risk), and 20 healthy individuals during the study period. The concentrations of nuclear and mtDNA were significantly higher in the AMI group on hospital day 1 than that in the non-MI controls (nuclear: 0.4948 +/- 0.0830 vs. 0.2047 +/- 0.0222 ng/mu l, P<0.05; mitochondrial: 3.754 +/- 0.384 vs. 1.851 +/- 0.3483 ng/mu l, P < 0.05) and healthy individuals (nuclear: 0.4948 +/- 0.0830 vs. 0.1683 +/- 0.0254 ng/mu l, P=0.001; mitochondrial: 3.754 +/- 0.384 vs. 0.1517 +/- 0.0924 ng/mu l, P < 0.05) and decreased shortly after PCI. Conclusion Both plasma nuclear and mtDNA levels are elevated in AMI patients, but return to normal levels immediately after PCI, suggesting that they are potentially novel biomarkers for AMI. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.